Yarrow Bioscience sells 5,769,231 shares at $26.00, with net proceeds of about $161.8 million
Yarrow Bioscience entered an underwriting agreement on September 10, 2026, to sell 5,769,231 common shares at $26.00 per share, and the underwriters exercised in full their option to buy 865,384 more shares on September 11, 2026. The company expects net proceeds of about $161.8 million, with closing expected on September 14, 2026. The sale adds new shares outstanding, which dilutes existing shareholders, and directors and executive officers agreed to a 60-day lock-up on selling their shares.
Key points
- Base offering of 5,769,231 shares at $26.00 per share, underwritten by Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC
- Underwriters exercised in full their 30-day option on September 11, 2026, for up to 865,384 additional shares
- Expected net proceeds of about $161.8 million after underwriting discounts and estimated offering expenses
- Offering made under a Form S-3 shelf registration effective August 19, 2026; closing expected September 14, 2026; directors and executive officers subject to a 60-day lock-up
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.